Wang et al. demonstrated that RUNX1 negatively regulates miR-101 expression in lung cancer cells, thereby hindering the sensitizing effect of miR-101 on cisplatin in lung cancer chemotherapy [173]. Here, RUNX1 is linked to lung carcinoma.